Occasionally, a one fear grows so significant that it obscures all the very good matters taking place at the similar time. Which is the case with the inventory of pharma large
AbbVie
whose blockbuster drug Humira faces patent expirations.
Humira is an immunosuppressive that is racked up just about $200 billion in revenue since its 2002 approval. AbbVie (ticker: ABBV) has fought fiercely to lengthen its exclusivity of Humira, which treats problems from rheumatoid arthritis to Crohn’s sickness, but it has by now shed patent protection in Europe and faces improved level of competition from biosimilars in the U.S., starting up coming year.
Occasionally, a one fear grows so significant that it obscures all the very good matters taking place at the similar time. Which is the case with the inventory of pharma large
AbbVie
whose blockbuster drug Humira faces patent expirations.
Humira is an immunosuppressive that is racked up just about $200 billion in revenue since its 2002 approval. AbbVie (ticker: ABBV) has fought fiercely to lengthen its exclusivity of Humira, which treats problems from rheumatoid arthritis to Crohn’s sickness, but it has by now shed patent protection in Europe and faces improved level of competition from biosimilars in the U.S., starting up coming year.
